A new multi-center, randomized controlled trial aims to evaluate the effectiveness of low-energy-density (LED) red light devices in controlling the progression of myopia in children. This trial, sponsored by Shanghai General Hospital, is still in the planning stages and is described as “not yet recruiting,” with an anticipated launch in the near future.
The study will assess the dose-response relationship of LED red light exposure and compare its outcomes with another intervention, the Hoya DIMS (Defocus Incorporated Multiple Segments) lenses. Clinical, regulatory, and quality professionals may find this development noteworthy as it explores innovative approaches to mitigate the global public health burden of myopia, also known as nearsightedness.
In this article
- What changed?
- Who is involved?
- What is the aim of the trial?
- What are the studied devices?
- FAQs
- Conclusion
- Disclaimer
- Where to find more details?
What changed?
This trial introduces LED red light devices to myopia management, a treatment method that is being clinically evaluated for its efficacy. The evidence around such interventions is growing as stakeholders prioritize public health solutions to control progressive myopia in children.
The study’s unique focus on dose-response evaluation adds a layer of scientific rigor to understanding how light-based therapies can be optimized. With paired interventions like the Hoya DIMS lens, this effort addresses multiple treatment modalities in a single design.
Who is involved?
The trial is sponsored by Shanghai General Hospital in collaboration with Shanghai Jiao Tong University School of Medicine. These institutions have a track record of contributing to ophthalmologic research.
Two devices will be compared in this study: the Yingtong Vision Rehabilitation Instrument (an LED red light device) and the Hoya DIMS lens, a spectacle lens designed to provide myopic defocus while preserving clear vision.
What is the aim of the trial?
Myopia has become a significant public health concern, with increasing prevalence worldwide, particularly among children and young adults. This trial will aim to study how LED red light therapy impacts the progression of myopia and whether clear dose-response patterns can be observed.
The trial will also examine how this modality compares with the established Hoya DIMS spectacle lens, providing insights into which approach—or combination—is more effective in managing myopia progression.
Beyond establishing effectiveness, researchers will evaluate compliance, usability, and any unintended side effects through data collection and monitoring frameworks.
What are the studied devices?
The Yingtong Vision Rehabilitation Instrument is a medical device that uses LED-generated red light. Red light mechanisms have demonstrated potential for reducing axial elongation—a key indicator of myopia progression—through earlier studies. However, data on its dose-response relationship is sparse, making this study all the more relevant.
Meanwhile, the Hoya DIMS lens, already in use as a myopia management tool, is gaining ground as a non-invasive intervention. By creating multiple blurred and clear zones on the lens surface, it manages the eye’s focus, preventing the elongation of the eyeball associated with myopia progression.
Both devices are compliant with medical device regulatory frameworks and aim to offer low-risk treatment strategies.
FAQ
- Who can participate in this study?
The trial is designed for children with progressive myopia. Specific eligibility criteria will be clarified when the recruitment stage begins. - Is the study already recruiting participants?
No, the study status is listed as “not yet recruiting.” Updates can be tracked on ClinicalTrials.gov using the link provided below. - Why is dose-response evaluation important?
Understanding the optimal dose of LED red light may enhance treatment efficacy, lower risks, and support personalized therapeutic approaches. - Where can I find more information?
Detailed information is available on the ClinicalTrials.gov listing linked below.
Conclusion
This trial represents a critical step in advancing myopia management through emerging technologies. Regulatory, clinical, and design professionals in the medical device sector should monitor this trial as a case study in innovation-driven healthcare solutions.
Disclaimer
This content is provided for information purposes only and does not constitute medical, legal, or regulatory advice. Stakeholders should seek specialized advice related to their context.
Where to find more details?
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07330180?term=medical+device